 SAN DIEGO, May 11, 2021 PRNewswire -- Poseida Therapeutics, Inc. Nasdaq: PSTX, a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced program updates and financial results for the first quarter ended March 31, 2021. We are encouraged by our continued progress in first quarter of 2021, building on the accomplishments from the prior year as we moved multiple programs forward to important inflection points, including our ongoing P-BCMA-101 and P-PSMA-101 CAR-T programs, on which we plan to provide further clinical updates later in the year, said Eric Ostertag, M.D. 